We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Product
Advertisement
Sino Biological Inc logo

GDNF: A Neurotrophic and Neuroprotective Factor

GDNF: A Neurotrophic and Neuroprotective Factor


Sino Biological Inc logo

Glial cell line-derived neurotrophic factor (GDNF) plays a vital role in promoting motor neuron survival and axon outgrowth. It is being evaluated in clinical trials as a potential therapeutic for Parkinson’s disease. GFL-like drugs are also being developed to treat disorders such as neuropathic pain and addiction.


GDNF belongs to the GDNF family of ligands (GFLs), which also consists of neurturin (NRTN), artemin (ARTN), and persephin (PSPN). These molecules bind to GFRA1, GFRA2, GFRA3, and GFRA4, respectively. GDNF/GFRA1 complex triggers the phosphorylation of RET tyrosine kinase receptor, ultimately eliciting cell survival, proliferation, and development via the MAPK/ERK or PI3K/Akt pathways. GDNF/GFRA1 also complexes with NCAM to induce axonal expansion. In addition, GDNF can synergize with other growth factors, including transforming growth factor-β (TGF-beta).


Sino Biological has developed an array of recombinant GDNF and GFRA1 proteins and antibodies from various species, such as human, mouse, cynomolgus, rabbit, rat, and canine.



About Sino Biological Inc
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates